Rigel Pharmaceuticals (RIGL)
30.16
-0.09 (0.30%)
Upcoming Events
Latest Headlines
Form 4 RIGEL PHARMACEUTICALS For: Jun 01 Filed by: Schorno Dean L
June 3, 2026 6:04 PM - SEC Filing
Form 4 RIGEL PHARMACEUTICALS For: Jun 01 Filed by: Santos David A
June 3, 2026 6:03 PM - SEC Filing
Form 4 RIGEL PHARMACEUTICALS For: Jun 01 Filed by: Rojkjaer Lisa
June 3, 2026 6:02 PM - SEC Filing
Form 4 RIGEL PHARMACEUTICALS For: Jun 01 Filed by: RODRIGUEZ RAUL R
June 3, 2026 6:02 PM - SEC Filing
Form 4 RIGEL PHARMACEUTICALS For: Jun 01 Filed by: Furey Raymond J.
June 3, 2026 6:01 PM - SEC Filing
Form 4 RIGEL PHARMACEUTICALS For: May 26 Filed by: Ali-Jackson Kamil
May 28, 2026 5:05 PM - SEC Filing
Rigel to Present at the Jefferies Global Healthcare Conference
May 27, 2026 8:05 AM - PR NewsWire
Form 144 RIGEL PHARMACEUTICALS Filed by: Ali-Jackson Kamil
May 26, 2026 10:43 AM - SEC Filing
Rigel to present cancer drug trial data at major medical conferences
May 21, 2026 5:36 PM - StreetInsider
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
May 21, 2026 5:17 PM - PR NewsWire
Form 8-K RIGEL PHARMACEUTICALS For: May 14
May 20, 2026 4:10 PM - SEC Filing
Form 4 RIGEL PHARMACEUTICALS For: May 15 Filed by: Wasman Jane
May 19, 2026 8:51 PM - SEC Filing
Form 4 RIGEL PHARMACEUTICALS For: May 15 Filed by: MOOS WALTER H
May 19, 2026 8:50 PM - SEC Filing
Form 4 RIGEL PHARMACEUTICALS For: May 15 Filed by: MILLER MICHAEL PATRICK
May 19, 2026 8:50 PM - SEC Filing
Form 4 RIGEL PHARMACEUTICALS For: May 15 Filed by: LAPOINTE ANTHONY GREGG
May 19, 2026 8:50 PM - SEC Filing
Form 4 RIGEL PHARMACEUTICALS For: May 15 Filed by: HANNAH ALISON L.
May 19, 2026 8:49 PM - SEC Filing
Form 4 RIGEL PHARMACEUTICALS For: May 15 Filed by: Frohlich Mark W
May 19, 2026 8:49 PM - SEC Filing
Form 4 RIGEL PHARMACEUTICALS For: May 15 Filed by: Ali-Jackson Kamil
May 19, 2026 8:48 PM - SEC Filing
Form SCHEDULE 13G RIGEL PHARMACEUTICALS Filed by: ARMISTICE CAPITAL, LLC
May 15, 2026 11:33 AM - SEC Filing
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
May 14, 2026 8:05 AM - PR NewsWire
Form 8-K RIGEL PHARMACEUTICALS For: May 11
May 12, 2026 5:25 PM - SEC Filing
Rigel licenses VEPPANU breast cancer drug for $85 million upfront
May 12, 2026 7:02 AM - StreetInsider
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
May 12, 2026 7:00 AM - PR NewsWire
Form SCHEDULE 13G RIGEL PHARMACEUTICALS Filed by: Soleus Capital Master Fund, L.P.
May 7, 2026 5:02 PM - SEC Filing
Rigel Pharmaceuticals (RIGL) Tops Q1 EPS by 44c
May 5, 2026 4:55 PM - StreetInsider
Form 8-K RIGEL PHARMACEUTICALS For: May 05
May 5, 2026 4:09 PM - SEC Filing
Form 10-Q RIGEL PHARMACEUTICALS For: Mar 31
May 5, 2026 4:07 PM - SEC Filing
Rigel Reports First Quarter 2026 Financial Results
May 5, 2026 4:01 PM - PR NewsWire
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
April 28, 2026 8:05 AM - PR NewsWire
Rigel Pharmaceuticals regains rights as Lilly terminates license deal
April 21, 2026 4:22 PM - StreetInsider
Form 8-K RIGEL PHARMACEUTICALS For: Apr 16
April 21, 2026 4:18 PM - SEC Filing
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
April 7, 2026 12:39 PM - PR NewsWire
Form DEFA14A RIGEL PHARMACEUTICALS
April 3, 2026 4:03 PM - SEC Filing
Form DEF 14A RIGEL PHARMACEUTICALS For: May 14
April 3, 2026 4:02 PM - SEC Filing
Rigel publishes final ARROW trial data for pralsetinib in lung cancer
March 31, 2026 8:07 AM - StreetInsider
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
March 31, 2026 8:05 AM - PR NewsWire
Form SCHEDULE 13G/A RIGEL PHARMACEUTICALS Filed by: VANGUARD GROUP INC
March 27, 2026 11:39 AM - SEC Filing
Full Article List
